Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]
A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.
Ibrutinib, a Novel Agent in Relapsed or Refractory Chronic Lymphocytic Leukemia
Refractory or relapsed chronic lymphocytic leukemia is still a hematologic malignancy with an unfavorable evolution after several lines of chemotherapy, even when associated with immunotherapy.
The additional presence of adverse prognostic factors such as17p deletion, 11 q deletion, unmutated IgVH genes, CD 38 and ZAP 70 expression further limits therapeutic possibilities.
Over the past two years numerous studies have focused on finding new therapeutic options useful in cases of relapsed or refractory chronic lymphocytic leukemia.
Ibrutinib is a new agent that has shown efficacy in treating these cases, the benefits of response and survival rate having been obtained using Ibrutinib as monotherapy, as well as in combination with immunotherapy or chemotherapy